Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Ovarian Neoplasms 16Neoplasms 6Breast Neoplasms 6Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Stomach Neoplasms 1Prostate Adenocarcinoma 1Pancreatic Adenocarcinoma 1Osteosarcoma 1Oligodendroglioma 1Neuroblastoma 1Metastatic Castration-sensitive Prostate Cancer 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

enzalutamide 6Abiraterone Acetate 4niraparib 2Prednisone 2xentuzumab 1tasquinimod 1pembrolizumab 1darolutamide 1atezolizumab 1abiraterone 1Nivolumab 1Drug Therapy 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Prostatic Neoplasms, Castration-Resistant × niraparib × Clear all
NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡